多西他赛联合卡培他滨治疗局部晚期胃癌的疗效观察  

Clinical efficacy of docetaxel plus capecitabine in the treatment of local gastric cancer

作　　者：曾娟紫[1] 吴国武[1] 王悦冬[1] 廖志东[1] 

机构地区：[1]广东省梅州市人民医院,梅州514031

出　　处：《中国肿瘤临床与康复》2014年第7期831-833,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察多西他赛联合卡培他滨对局部晚期胃癌的疗效。方法选取50例局部晚期胃癌患者,给予多西他赛联合卡培他滨方案治疗(观察组),同时选取50例单用多西他赛治疗的患者作为对照组,观察两组患者近期疗效、生存率及化疗不良反应等。结果观察组患者近期治疗有效率为70.0%,对照组为56.0%,差异有统计学意义(P<0.05)。观察组患者的1、2、3年生存率分别为74.0%、56.0%和52.0%,对照组患者的1、2、3年生存率分别为54.0%、40.0%和28.0%,差异有统计学意义(P<0.05)。骨髓抑制与消化道反应是较为多见的不良反应,但两组PLT计数降低、WBC计数降低、肝肾损害、腹泻、呕吐恶心、脱发等方面差异均无统计学意义(P>0.05)。结论多西他赛联合卡培他滨治疗局部晚期胃癌近期临床效果较佳,且不良反应发生率较低。Objective To observe the clinical effects of docetaxel plus capecitabine for treatment of local gastric cancer. Methods 50 patients with local gastric cancer were chosen and given treatment of do- cetaxel plus capecitabine. Meanwhile, another 50 patients were chosen as control group and given merely do- cetaxel for treatment. Short term clinical effects, medium-term survival rates and toxic and side effects of chemotherapy of the two groups were observed. Results Short term effective rate（CP ＋ PR） of observation group was 70. 0%, which was higher than that of the control group （ 56. 0%, P 〈 0. 05 ）. On medium-term survival rate, 1 year,2 year and 3 year survival rate of observation group were separately 74. 0% ,56. 0% and 52. 0% ,which were obviously higher than those of the control group （54.0%, 40. 0% and 28.0%, P 〈 0. 05）. On toxic and side effects, bone marrow suppression and gastrointestinal reaction were common toxic and side effects. But there were no significant differences between the two groups on decrease of WBC count, decrease of PLT count, baldness, nausea and vomiting, diarrhea and liver and kidney function （ P 〉 0. 05 ）. Conclusion Docetaxel plus capecitabine for treatment of patients with local gastric cancer has good short term clinical effects,improve medium-term survival rate of patietns, and has low occurrence rate of toxic and side effects.

关 键 词：胃肿瘤 药物疗法 治疗结果 

分 类 号：R735.2[医药卫生—肿瘤]